Compare Abeona Therapeutics Inc (ABEO) vs Banco Santander SA (SAN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Banco Santander SA — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Banco Santander SA trades at $13.59 (market cap $203.67B). The key difference: Banco Santander SA is far larger — about 545.6× Abeona Therapeutics Inc's market cap, and Banco Santander SA pays a 1.96% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | SAN | |
|---|---|---|
Market Cap | $373.32M | $203.67B |
Sector | Health | Financials |
52-Week High | $7.23 | $14.37 |
52-Week Low | $4.17 | $8.31 |
Enterprise Value | $228.22M | — |
Dividend Yield | — | 1.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Banco Santander (SAN) trades at $14.19, up 1.72% today, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a 26.72% net income margin and 16.18% ROE, though recent quarters saw EPS misses. Recent developments include the completion of the TSB acquisition and AI-driven efficiency initiatives, positioning the company for growth amid positive analyst sentiment.
The outlook for SAN is cautiously optimistic, with upside driven by cost-saving measures and strategic acquisitions. Risks include regulatory scrutiny in Spain and volatile cash flows. Analysts maintain a 64% buy rating, highlighting value potential, but investors should monitor execution on profitability targets and macroeconomic impacts on banking sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
